Twist Bioscience Collaborates with Synthetic Design Lab

SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Sep. 2, 2025 — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL).

“With our high throughput expertise, from novel binder discovery services to high throughput screening capabilities, we’re able to support researchers working to unlock novel engineered therapeutics,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We are uniquely positioned to support Synthetic Design Lab’s development of novel antibody-drug conjugates for various cancer types.”

“Collaborating with Twist, we’re able to leverage their extensive suite of high throughput services to help us advance on our mission to unlock the full potential of our proprietary approach,” said Daniel S. Chen, M.D., Ph.D., Chief Executive Officer of Synthetic Design Lab. “We believe that with our SYNTHBODY platform, we can develop a broad suite of therapeutics that are far more advanced than what is available today.”